Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Research Grant, 2014
    Tumorigenesis in Parkinson’s Disease

    Objective/Rationale:             
    The aim of the study is to investigate whether disease-causing genetic mutations in Parkinson’s disease (PD), particularly in the LRRK2 gene, also predispose...

  • Target Validation, 2014
    Targeted Disruption of TRIM28 to Reduce Alpha-synuclein Levels

    Objective/Rationale:
    We have previously performed a screen to find new pathways that may regulate alpha-synuclein, the toxic protein that accumulates in the cells of people with Parkinson’s disease (PD...

  • Target Validation, 2014
    Validating BAG5 as a Therapeutic Target of Parkinson’s Disease

    Objective/Rationale:
    Poor handling and elimination of misfolded proteins has been identified as central in the development of Parkinson’s disease (PD). A special class of proteins within the cell...

  • Rapid Response Innovation Awards, 2014
    Intrabodies in Pre-clinical Models of Parkinson’s Disease

    Objective/Rationale:
    Progressive loss of dopamine neurons and clumps of the protein alpha-synuclein are hallmarks of Parkinson’s disease (PD). Intrabodies are small antibody fragments that target...

  • Rapid Response Innovation Awards, 2014
    Cofilin-1 as a Major Contributor to Oxidative Stress-mediated Cell Death in Parkinson’s Disease

    Objective/Rationale:
    Oxidative stress, a process that stops the cell producing energy efficiently, is a key cause of the death of neurons in Parkinson’s disease. We have previously shown that oxidative...

  • Therapeutic Pipeline Program, 2014
    Characterization of a Novel Therapy To Selectively Silence Alpha-Synuclein In Monoaminergic Neurons

    Objective/Rationale:
    The biotech company nLife Therapeutics has designed a molecule (NLF-PD-1233) to target specific neurons in the brain to reduce expression of the protein alpha-synuclein (which...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.